在CATIE数据发布前后抗精神病药物的使用情况。
Use of Antipsychotics Pre- and Post-Dissemination of CATIE Data.
作者信息
Cascade Elisa F, Kalali Amir H, Lieberman Jeffrey, Hsiao John, Keefe Richard, Stroup Scott
机构信息
Ms. Cascade is Vice President, Strategic Research and Safety, Quintiles Inc., Falls Church, Virginia.
出版信息
Psychiatry (Edgmont). 2007 May;4(5):21-3.
We investigated the share of branded and generic antipsychotics before and after the publication of the CATIE results in September, 2005. According to our data, the publication of the CATIE results has had very little impact on new patient starts. To determine the impact of CATIE on use of olanzapine (Zyprexa((R))) subsequent to first line therapy, we also examined product share for switch/add patients. We found that since the publication of the CATIE results, the use of olanzapine has stabilized, following a decline subsequent to first line therapy, and may potentially be growing very slowly. An expert commentary is provided on the data.
我们调查了2005年9月《临床抗精神病药物干预有效性研究（CATIE）》结果公布前后品牌和非专利抗精神病药物的使用占比。根据我们的数据，CATIE结果的公布对新患者的起始用药影响甚微。为确定CATIE对一线治疗后奥氮平（再普乐（R））使用情况的影响，我们还研究了换药/加药患者的产品使用占比。我们发现，自CATIE结果公布以来，奥氮平的使用在一线治疗后下降，之后趋于稳定，且可能正以非常缓慢的速度增长。文中还提供了关于这些数据的专家评论。
Zotero 插件